Stock Events

Stock Events

Alzamend Neuro 

$1.6600
65
-$0.01-0.3% 11:00 Today

Statistics

Day High
1.665
Day Low
1.665
52W High
2.68
52W Low
0.84
Volume
1,433
Avg. Volume
-
Mkt Cap
8.03M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15SepExpected
Q3 2024
Q4 2024
Q2 2025
Q2 2025
Q3 2025
Q4 2025
Next
-3.2
-2.23
-1.27
-0.3
Expected EPS
-0.56
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-8.77MNet Income

Analyst Ratings

26.00Average Price Target
The highest estimate is 26.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALZN. It's not an investment recommendation.
Amazon
13
AMZN
NVIDIA
13
NVDA
Microsoft
10
MSFT
Tesla
9
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.03B
Biogen is a leading company in the development of therapies for neurological diseases, including Alzheimer's, directly competing with Alzamend's focus.
Lilly(Eli) &
LLY
Mkt Cap1.12T
Eli Lilly has advanced clinical trials for Alzheimer's treatments, positioning it as a direct competitor in the Alzheimer's disease treatment market.
Anavex Life Sciences
AVXL
Mkt Cap300.34M
Anavex Life Sciences Corp. specializes in developing novel therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer's.
AC Immune SA
ACIU
Mkt Cap288.34M
AC Immune SA focuses on precision medicine for neurodegenerative diseases, including Alzheimer's, making it a competitor in the same therapeutic area.
Prothena
PRTA
Mkt Cap485.13M
Prothena Corporation plc is involved in the development of therapies for neurodegenerative diseases, including Alzheimer's disease, directly competing with Alzamend.
Axsome Therapeutics
AXSM
Mkt Cap10.88B
Axsome Therapeutics, Inc. works on developing therapies for central nervous system disorders, which could include Alzheimer's disease and other areas of interest to Alzamend.
Annovis Bio
ANVS
Mkt Cap77.54M
Annovis Bio Inc. is engaged in developing drug therapies for Alzheimer's and Parkinson's diseases, placing it in direct competition with Alzamend's Alzheimer's focus.

About

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Show more...
CEO
Stephan Jackman
Employees
6
Country
United States
ISIN
US02262M6057
WKN
000A3EYCP

Listings

STU
DE
9ZT0.STU
MU
DE
9ZT0.MU
XNAS
US
ALZN
BOATS
BOATS
ALZN.BOATS

0 Comments

Share your thoughts

FAQ

What is Alzamend Neuro stock price today?▼
The current price of ALZN is $1.66 USD — it has decreased by -0.3% in the past 24 hours. Watch Alzamend Neuro stock price performance more closely on the chart.
What is Alzamend Neuro stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Alzamend Neuro stocks are traded under the ticker ALZN.
Is Alzamend Neuro stock price growing?▼
ALZN stock has risen by +6.73% compared to the previous week, the month change is a +27.1% rise, over the last year Alzamend Neuro has showed a -31.48% decrease.
What is Alzamend Neuro market cap?▼
Today Alzamend Neuro has the market capitalization of 8.03M
When is the next Alzamend Neuro earnings date?▼
Alzamend Neuro is going to release the next earnings report on September 15, 2026.
What were Alzamend Neuro earnings last quarter?▼
ALZN earnings for the last quarter are -0.58 USD per share, whereas the estimation was -0.53 USD resulting in a -9.43% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alzamend Neuro revenue for the last year?▼
Alzamend Neuro revenue for the last year amounts to 0 USD.
What is Alzamend Neuro net income for the last year?▼
ALZN net income for the last year is -8.77M USD.
How many employees does Alzamend Neuro have?▼
As of August 28, 2026, the company has 6 employees.
In which sector is Alzamend Neuro located?▼
Alzamend Neuro operates in the Health & Wellness sector.
When did Alzamend Neuro complete a stock split?▼
The last stock split for Alzamend Neuro was on May 12, 2025 with a ratio of 1:9.
Where is Alzamend Neuro headquartered?▼
Alzamend Neuro is headquartered in ATLANTA, United States.